The MG composite: An outcome measure for myasthenia gravis for use in clinical trials and everyday practice

Annals of the New York Academy of Sciences

Volumn 1274, Issue 1, 2012, Pages 99-106

  Burns, Ted M ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

MG; MG composite; MGC; Myasthenia gravis; Outcome measures

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); HUMAN; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS COMPOSITE SCALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; RATING SCALE; TEST RETEST RELIABILITY; VALIDATION STUDY;

EID: 84871262099     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06812.x     Document Type: Article

References (32)

1. Meriggioli, M.N. & D.B. Sanders. 2009. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 8: 475-490.
2. Tindall, R.S.A., J.A. Rollins, J.T. Phillips, et al. 1987. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N. Engl. J. Med. 316: 719-724.
3. Mantegazza, R., C. Antozzi, D. Pelucchetti, et al. 1988. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J. Neurol. 235: 449-453.
4. Tindall, R.S.A., J.T. Phillips, J.A. Rollins, et al. 1993. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. N.Y. Acad. Sci. 681: 539-551.
5. Barohn, R.J., D. McIntire, L. Herbelin, et al. 1998. Reliability testing of the quantitative myasthenia gravis score. Ann. N.Y. Acad. Sci. 841: 769-772.
6. Wolfe, G.I., L. Herbelin, S.P. Nations, et al. 1999. Myasthenia gravis activities of daily living profile. Neurology 52: 1487-1489.
7. Jaretzki, A., R.J. Barohn, R.M. Ernstoff, et al.; for the Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. 2000. Myasthenia gravis: recommendations for clinical research standards. Neurology 55: 16-23.
8. Sharshar, T., S. Chevret, M. Mazighi, et al. 2000. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. J. Neurol. 247: 286-290.
9. Barohn, R.J. 2003. Standards of measurement in myasthenia gravis. Ann. N.Y. Acad. Sci. 998: 432-439.
10. Sanders, D.B., B. Tucker-Lipscomb & J.M. Massey. 2003. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann. N.Y. Acad. Sci. 998: 440-444.
11. Gajdos, P., T. Sharshar & S. Chevret. 2003. Standards of measurements in myasthenia gravis. Ann. N.Y. Acad. Sci. 998: 445-452.
12. Bedlack, R.S., D.L. Simel, H. Bosworth, et al. 2005. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 64: 1968-1970.
13. Padua, L., G. Galassi, A. Ariatti, et al. 2005. Myasthenia gravis self-administered questionnaire: development of regional domains. Neurol. Sci. 25: 331-336.
14. Farrugia, M.E., M.D. Robson, L. Clover, et al. 2006. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129: 1481-1492.
15. Burns, T.M., M.R. Conaway, G.R. Cutter & D.B. Sanders. 2008. The construction of an efficient evaluative instrument for myasthenia gravis: the MG Composite. Muscle Nerve 38: 1553-1562.
16. Burns, T.M., M.R. Conaway, D.B. Sanders, et al. 2010. The MG composite: a valid and reliable tool for myasthenia gravis. Neurology 74: 1434-1440.
17. Burns, T.M. 2010. A history of outcome measures in myasthenia gravis. Muscle Nerve 42: 5-13.
18. Burns, T.M., C.K. Grouse, M.R. Conaway, et al. 2010. Construct and concurrent validation of the MG-QOL15 in the practice setting. Muscle Nerve 41: 219-226.
19. Farrugia, M.E., H. Harle, C. Carmichael & T.M. Burns 2011. The oculobulbar facial respiratory score is a tool to assess bulbar function in myasthenia gravis patients. Muscle Nerve 43: 329-334.
20. Burns, T.M., C.K. Grouse, M.R. Conaway, et al. 2011. The MG-QOL15 for following the health-related quality of life for patients with myasthenia gravis. Muscle Nerve 43: 14-18.
21. Muppidi, S., G.I. Wolfe, M. Conaway, et al. 2011. MG-ADL: still a relevant outcome measure. Muscle Nerve 44: 721-731.
22. Zinman, L. & V. Bril. 2008. IVIG treatment for myasthenia gravis. Effectiveness, limitations, and novel therapeutic strategies. Ann. N.Y. Acad. Sci. 1132: 264-270.
23. Sanders, D.B., I.K. Hart, R. Mantegazza, et al. 2008. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71: 400-406.
24. Muscle Study Group. 2008. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71: 394-399.
25. Wolfe, G.I., R.J. Barohn, D.B. Sanders, et al. 2008. Comparison of outcome measures from a trial of mycophenolate mofetil in myasthenia gravis. Muscle Nerve 38: 1429-1433.
26. Barth, D., M. Nabavi Nouri, E. Ng, et al. 2011. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76: 2017-2023.
27. Tompkins, C.P., A.R. Higgins & G.A. Ritter. 2009. Measuring outcomes and efficiency in medicare value-based purchasing. Health Affairs 28: w251-w261.
28. Miller, T.P., T.A. Brennan & A. Milstein 2009. How can we make more progress in measuring physicians' performance to improve the value of care Health Affairs 28: 1429-1437.
29. Guptill, J.T., B.K. Sharma, A. Marano, et al. 2012. Estimated cost of treating myasthenia gravis in an insured U.S. population. Muscle Nerve 45: 363-366.
30. Matsuda, M., K. Utsugisawa, S. Sukuki, et al. 2012. The MG-QOL15 Japanese version: validation and associations with clinical factors. Muscle Nerve 46: 166-173.
31. Sadjadi, R., M. Conaway, G.R. Cutter, et al. 2012. Psychometric evaluation of the MG Composite using Rasch analysis. Muscle Nerve 45: 820-825.
32. Benatar, M., D.B. Sanders, T.M. Burns, et al. 2012. Recommendations for myasthenia gravis clinical trials. Muscle Nerve 45: 909-917.